Hormonal
GLP-1 receptor agonists (GLP-1RAs) reduce cardiovascular risk and body weight in obese patients with pre-existing cardiovascular disease, regardless of diabetes status, by modulating metabolic pathways, reducing inflammation, and slowing gastric emptying.
If you are overweight or obese and have existing heart disease, GLP-1 receptor agonists like semaglutide are a proven treatment to lower your risk of heart attacks, strokes, and death from heart causes, even if you don't have diabetes. These drugs work by mimicking a hormone that helps control blood sugar, reduces appetite, and slows digestion. While they are injections, their ability to protect your heart and reduce weight makes them a critical tool for secondary prevention. Always discuss with your doctor if this is right for you, especially regarding side effects and dosing.
In this contest, agonists of the glucagon-like peptide-1 receptor (GLP-1RAs) modulate different metabolic pathways associated with glucose metabolism, energy homeostasis, antioxidation, and inflammation... Recently, in overweight or obese patients with pre-existing cardiovascular disease but without diabetes, the GLP-1RA semaglutide reduced the incidence of cardiovascular and cerebrovascular events and death from cardiovascular causes.
Why this rating
The paper cites specific clinical outcomes (reduced incidence of events) and approval for secondary prevention, indicating strong clinical evidence, though it is a review paper.
Source
Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management
Giovanna Gallo et al. · Nutrients · 2024
DOI 10.3390/nu16162781
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →